HomeONC • TSE
add
Oncolytics Biotech Inc
Previous close
$0.69
Day range
$0.65 - $0.70
Year range
$0.65 - $2.08
Market cap
57.73M CAD
Avg Volume
58.16K
P/E ratio
-
Dividend yield
-
In the news
Financials
Income Statement
Revenue
Net income
| (CAD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 7.00M | -19.79% |
Net income | -6.69M | 3.00% |
Net profit margin | — | — |
Earnings per share | -0.08 | 11.11% |
EBITDA | -6.97M | 19.83% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (CAD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 15.30M | -48.31% |
Total assets | 19.70M | -43.30% |
Total liabilities | 13.21M | 12.11% |
Total equity | 6.49M | — |
Shares outstanding | 84.63M | — |
Price to book | 8.62 | — |
Return on assets | -87.73% | — |
Return on capital | -240.66% | — |
Cash Flow
Net change in cash
| (CAD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -6.69M | 3.00% |
Cash from operations | -6.50M | 13.00% |
Cash from investing | — | — |
Cash from financing | 5.89M | 293.98% |
Net change in cash | -639.00K | 87.96% |
Free cash flow | -5.46M | 0.70% |
About
Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. Wikipedia
Founded
1998
Headquarters
Website
Employees
28
